Apex Labs
Apex Labs is a veteran-founded company that develops psilocybin treatments for depression and PTSD, aiming to establish these as a new standard in mental health care.
Psilocybin Treatments for Depression and PTSD
Apex Labs focuses on developing and commercializing clinically evaluated psilocybin treatments specifically targeting depression and PTSD. The company dedicates its resources to establish psilocybin-based therapies as a preferred alternative to traditional antidepressants in mental health care. Through rigorous clinical programs, Apex Labs evaluates the safety and efficacy of its drug candidates to ensure effectiveness.
Clinical Programs and Drug Candidates
Apex Labs conducts multiple clinical trials to test their psilocybin treatments' safety and efficacy. Notable among these are two main drug candidates - APEX-52, a microdose drug optimized for take-home use, and APEX-90, a macrodose drug intended for in-clinic administration. These clinical programs are essential for pursuing regulatory approval and ensuring their treatments meet the necessary safety standards.
Veteran-Focused Clinical Trials and Early Access Programs
Founded by veterans, Apex Labs prioritizes the veteran community in its clinical trials and Early Access Programs. This focus ensures the development of treatments that cater specifically to veterans' unique mental health needs. The company's commitment to veterans is evident in their targeted study designs and patient recruitment strategies.
Global Commercial Approval Efforts
Apex Labs is actively pursuing commercial approval for its psilocybin treatments across several significant markets, including the US, Canada, the UK, the EU, and Australia. These efforts follow the completion of their Canadian phase 2b study. By seeking approval in these regions, Apex Labs aims to expand access to their innovative treatments globally.
World's Largest Microdose Psilocybin Clinical Trial
Apex Labs has successfully completed the world's largest take-home microdose psilocybin clinical trial, which was approved by Health Canada. This milestone demonstrates the company's capacity to conduct extensive research and development activities. It also highlights Health Canada's confidence in Apex Labs' approach and the potential of their psilocybin-based therapies.